MedTrace Logo

Study of Vilazodone to Treat Social Anxiety Disorder

NCT01712321 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.

Conditions

Interventions

DRUG

Vilazodone

Vilazodone 20mg or 40mg taken once daily by mouth

DRUG

Placebo

Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • The Medical Research Network

    lead OTHER

Principal Investigators

  • Michael R. Liebowitz, MD · The Medical Research Network, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-03-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712321 on ClinicalTrials.gov